107 related articles for article (PubMed ID: 11573140)
1. Sodium/iodide symporter in thyroid cancer.
Mian C; Lacroix L; Bidart JM; Caillou B; Filetti S; Schlumberger M
Exp Clin Endocrinol Diabetes; 2001; 109(1):47-51. PubMed ID: 11573140
[No Abstract] [Full Text] [Related]
2. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
Carvalho DP; Ferreira AC
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas.
Saito T; Endo T; Kawaguchi A; Ikeda M; Katoh R; Kawaoi A; Muramatsu A; Onaya T
J Clin Invest; 1998 Apr; 101(7):1296-300. PubMed ID: 9525971
[TBL] [Abstract][Full Text] [Related]
4. Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells.
Haberkorn U; Beuter P; Kübler W; Eskerski H; Eisenhut M; Kinscherf R; Zitzmann S; Strauss LG; Dimitrakopoulou-Strauss A; Altmann A
J Nucl Med; 2004 May; 45(5):827-33. PubMed ID: 15136633
[TBL] [Abstract][Full Text] [Related]
5. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients.
Schlumberger M; Lacroix L; Russo D; Filetti S; Bidart JM
Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):260-9. PubMed ID: 17315034
[TBL] [Abstract][Full Text] [Related]
6. Expression of the human sodium/iodide symporter (hNIS) in xenotransplanted human thyroid carcinoma.
Smit JW; Schröder-van der Elst JP; Karperien M; Que I; Romijn JA; van der Heide D
Exp Clin Endocrinol Diabetes; 2001; 109(1):52-5. PubMed ID: 11573141
[TBL] [Abstract][Full Text] [Related]
7. Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line.
Smit JW; Schröder-van der Elst JP; Karperien M; Que I; Stokkel M; van der Heide D; Romijn JA
J Clin Endocrinol Metab; 2002 Mar; 87(3):1247-53. PubMed ID: 11889195
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the sodium/iodide symporter by retinoids--a review.
Schmutzler C
Exp Clin Endocrinol Diabetes; 2001; 109(1):41-4. PubMed ID: 11573138
[TBL] [Abstract][Full Text] [Related]
9. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells.
Schmutzler C; Winzer R; Meissner-Weigl J; Köhrle J
Biochem Biophys Res Commun; 1997 Nov; 240(3):832-8. PubMed ID: 9398654
[TBL] [Abstract][Full Text] [Related]
10. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.
Ringel MD; Anderson J; Souza SL; Burch HB; Tambascia M; Shriver CD; Tuttle RM
Mod Pathol; 2001 Apr; 14(4):289-96. PubMed ID: 11301345
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of iodide uptake and efflux in various human thyroid cancer cells by expressing sodium iodide symporter gene via a recombinant adenovirus.
Lee WW; Lee B; Kim SJ; Jin J; Moon DH; Lee H
Oncol Rep; 2003; 10(4):845-9. PubMed ID: 12792733
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy with sodium/iodide symporter in hepatocarcinoma.
Haberkorn U
Exp Clin Endocrinol Diabetes; 2001; 109(1):60-2. PubMed ID: 11573143
[TBL] [Abstract][Full Text] [Related]
13. Methylation status of genes in papillary thyroid carcinoma.
Smith JA; Fan CY; Zou C; Bodenner D; Kokoska MS
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1006-11. PubMed ID: 17938324
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells.
Shen WT; Wong TS; Chung WY; Wong MG; Kebebew E; Duh QY; Clark OH
Surgery; 2005 Dec; 138(6):979-84; discussion 984-5. PubMed ID: 16360381
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin.
Furuya F; Shimura H; Suzuki H; Taki K; Ohta K; Haraguchi K; Onaya T; Endo T; Kobayashi T
Endocrinology; 2004 Jun; 145(6):2865-75. PubMed ID: 14976143
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of arsenic trioxide in transformed human thyroid cells.
Fröhlich E; Czarnocka B; Brossart P; Wahl R
Thyroid; 2008 Nov; 18(11):1183-93. PubMed ID: 19014326
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
18. Iodine mediated mechanisms and thyroid carcinoma.
Liu XH; Chen GG; Vlantis AC; van Hasselt CA
Crit Rev Clin Lab Sci; 2009; 46(5-6):302-18. PubMed ID: 19958216
[TBL] [Abstract][Full Text] [Related]
19. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers.
Peyrottes I; Navarro V; Ondo-Mendez A; Marcellin D; Bellanger L; Marsault R; Lindenthal S; Ettore F; Darcourt J; Pourcher T
Eur J Endocrinol; 2009 Feb; 160(2):215-25. PubMed ID: 19029227
[TBL] [Abstract][Full Text] [Related]
20. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
